Connect with us


Republican Senator Launches Thread To Track Violent Crime By Illegal Aliens

Republican Senator Launches Thread To Track Violent Crime By Illegal Aliens

Authored by Joseph Lord via The Epoch Times (emphasis ours),




Republican Senator Launches Thread To Track Violent Crime By Illegal Aliens

Authored by Joseph Lord via The Epoch Times (emphasis ours),

Sen. Roger Marshall (R-Kansas) has launched a thread on X to track serious crimes committed by illegal aliens under President Joe Biden’s administration.

Sen. Roger Marshall (R-Kan.) speaks with reporters during a press conference in the U.S. Capitol in Washington on July 11, 2023. (Madalina Vasiliu/The Epoch Times)

The thread, which comes amid concerns over a border that critics have described as “porous,” will feature stories of violent crimes perpetrated by illegal aliens.

“Under the Biden administration, every state has become a border state, ultimately jeopardizing our national security,” Mr. Marshall told The Epoch Times. “This is not just another talking point but the reality of Joe Biden’s unprecedented border crisis.”

So far, the thread catalogues a series of stomach-churning crimes, including child murder, sexual assault, and traffic collisions.

“For the past three years, thousands of illegal aliens have entered our country; violent crime is on the rise; fentanyl is killing over 300 Americans a day, and a historic number of individuals with ties to terrorist organizations have been encountered at our southern border, ” Mr. Marshall said. “We are sharing the deadly consequences of a nation without borders that have been compounded by Democrats’ soft-on-crime policies.”

The service comes amid continuing concerns over unprecedented illegal immigration via the southern border..

Immediately after taking office, President Biden made a series of major changes to U.S. immigration policy—changes, Republicans say, that have contributed to the vast increase in illegal crossings since January 2021.

The numbers speak for themselves.

According to Department of Homeland Security statistics, there were roughly 2.4 million illegal alien encounters along the southern border across the entire four years of President Donald Trump’s administration.

By comparison, in only three years under President Biden, Customs and Border Patrol (CBP) has encountered over 6.5 million illegal aliens along the southern border since Jan. 2021.

Many of those apprehended by CBP will turn themselves over voluntarily before being paroled into the U.S. interior to await a court date to determine their eligibility to remain in the country.

But with such a large intake of illegal aliens, the courts have become overwhelmed. In some jurisdictions, these aliens won’t see a trial until after 2030.

And according to statistics, many will never turn up to court in the first place, instead choosing to take their chances as fugitives.

Meanwhile, tens of thousands of pounds of fentanyl, one of the deadliest drugs in the world, has also streamed in across the border.

Media interviews with those living in border towns reveal a nightmare scenario: many families refuse to leave their homes without a weapon; they’ve encountered dead bodies, drug smugglers, and human traffickers near their homes; children aren’t allowed outside to play without being closely watched by their guardians.

The policies pursued by the administration, according to whistleblowers, have effectively turned the U.S. government into a “middleman” for the human trafficking of children by cartels.

The border itself is littered with garbage and the discarded identification cards of foreign nationals from countries all around the world.

According to some reports, around 200 people on the terrorist watchlist have been caught trying to cross into the country; however, there are likely many more that were not caught, as DHS records 1.4 million known “gotaways” who successfully evaded Border Patrol and made it into the interior of the country.

Republicans Blame Biden

Republicans say the blame for this situation lies squarely with decisions made by President Biden upon taking office.

For instance, President Biden halted the construction of new border wall, even though many of the materials had already been purchased by the U.S. government. Since then, many of these materials have simply sat at the border with no plans to be used, effectively wasting the taxpayer money spent on the materials.

Additionally, President Biden reinstated the Obama-era policy of “catch and release.”

Catch and release allows illegal aliens to be released into the country after being arrested by border patrol agents. Under the conditions of their release, these illegal immigrants are expected to appear for a court hearing at a later date.

Even before the massive influx of illegal aliens since 2021, many of those detained for crossing into the United States illegally didn’t show up to court.

The Center for Immigration Studies, which describes itself as “a non-partisan, non-profit research organization,” found that about half of these released illegal immigrants failed to appear to court between 2015 and 2017 (pdf). In 2017, 43 percent did not show up to their court date.

Now, with courts overwhelmed and immigration cases being pushed as far out as the 2030s, that situation has only gotten worse.

Under DHS Secretary Alejandro Mayorkas, CBP has effectively been forced to roll out the red carpet for illegal aliens who so much as make a claim to asylum. This has been enabled in part by an app, the “CBP One” app, that allows illegal aliens to “check in” for a time to appear at the border.

President Biden also ended President Trump’s “Remain in Mexico” policy, which allowed the DHS to require that illegal immigrants stay in Mexico until their court date. This in effect meant that only those with a legitimate claim to asylum would so much as enter the United States.

President Biden suspended the program upon taking office, formally ending it in June 2021.

Last May, the clock also ran out on Title 42, a pandemic immigration authority that allowed CBP to turn away illegal aliens on grounds of public health.

Despite bipartisan pleas not to end the program, Mr. Mayorkas let it lapse in May.

Frustrated with the administration’s handling of the border, and lacking the support to impeach President Biden over it, House Republicans have turned their attention to Mr. Mayorkas.

Mr. Mayorkas is currently facing articles of impeachment in the House for “breach of trust” and “willful and systemic refusal to comply with the law.”

However, even if he’s impeached in the House, his removal from office is unlikely.

If he were impeached in the House, his case would go to the Senate, where 60 votes are needed for his removal from office. Democrats currently hold 51.

Tyler Durden Mon, 01/29/2024 - 18:20

Read More

Continue Reading


Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…



To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading


Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….



Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 


About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. 

Read More

Continue Reading


Another country is getting ready to launch a visa for digital nomads

Early reports are saying Japan will soon have a digital nomad visa for high-earning foreigners.



Over the last decade, the explosion of remote work that came as a result of improved technology and the pandemic has allowed an increasing number of people to become digital nomads. 

When looked at more broadly as anyone not required to come into a fixed office but instead moves between different locations such as the home and the coffee shop, the latest estimate shows that there were more than 35 million such workers in the world by the end of 2023 while over half of those come from the United States.

Related: There is a new list of cities that are best for digital nomads

While remote work has also allowed many to move to cheaper places and travel around the world while still bringing in income, working outside of one's home country requires either dual citizenship or work authorization — the global shift toward remote work has pushed many countries to launch specific digital nomad visas to boost their economies and bring in new residents.

Japan is a very popular destination for U.S. tourists. 


This popular vacation destination will soon have a nomad visa

Spain, Portugal, Indonesia, Malaysia, Costa Rica, Brazil, Latvia and Malta are some of the countries currently offering specific visas for foreigners who want to live there while bringing in income from abroad.

More Travel:

With the exception of a few, Asian countries generally have stricter immigration laws and were much slower to launch these types of visas that some of the countries with weaker economies had as far back as 2015. As first reported by the Japan Times, the country's Immigration Services Agency ended up making the leap toward a visa for those who can earn more than ¥10 million ($68,300 USD) with income from another country.

The Japanese government has not yet worked out the specifics of how long the visa will be valid for or how much it will cost — public comment on the proposal is being accepted throughout next week. 

That said, early reports say the visa will be shorter than the typical digital nomad option that allows foreigners to live in a country for several years. The visa will reportedly be valid for six months or slightly longer but still no more than a year — along with the ability to work, this allows some to stay beyond the 90-day tourist period typically afforded to those from countries with visa-free agreements.

'Not be given a residence card of residence certificate'

While one will be able to reapply for the visa after the time runs out, this can only be done by exiting the country and being away for six months before coming back again — becoming a permanent resident on the pathway to citizenship is an entirely different process with much more strict requirements.

"Those living in Japan with the digital nomad visa will not be given a residence card or a residence certificate, which provide access to certain government benefits," reports the news outlet. "The visa cannot be renewed and must be reapplied for, with this only possible six months after leaving the countr

The visa will reportedly start in March and also allow holders to bring their spouses and families with them. To start using the visa, holders will also need to purchase private health insurance from their home country while taxes on any money one earns will also need to be paid through one's home country.

Read More

Continue Reading